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 ABSTRACT 
 
Background: Urinalysis is an important component in the assessment of acute kidney injury (AKI). 
Proteonomics is a rapidly developing approach in the analysis of physiological states. Several 
techniques have been developed to screen for protein populations. In this regard SELDI-TOF is a 
technique based on mass spectroscopy that is being utilized in proteonomics research. 
 
Methods: For this study, clean catch or catheterized urine was collected from normals (n=18) and 
patients referred to the renal service with AKI. Based upon urine and serum chemistries, clinical 
parameters, and microscopic urinalysis, the urines were separated into those consistent with 
prerenal azotemia (n=17) and acute tubular necrosis (ATN) (n=29). Initially, 5 samples each were 
chosen from the pre-renal and ATN who had no preexisting renal disease. Other etiologies of AKI 
were not included in this analysis. The urine specimens were diluted 1:5 and deposited onto an H4 
ProteinChip array using 50% acetonitrile as the binding buffer. This system captured the greatest 
spectral range with the SELDI-TOF evaluation (compared to SAX, WCX2, IMAC, and NP1 
ProteinChips).  Low (250) and high (300) laser intensities were utilized to ionize and desorb the 
protein molecules; the spectra were collected in a positive ion mode and analyzed with Ciphergen 
Peaks software (v 3.0). 
 
Results: Five peaks with the high laser power were identified as potential candidates to discriminate 
between AKI due to prerenal or ATN causes. Those urines from the prerenal subjects were 
associated with detectable masses at 22.6 and 44.8 kilodaltons (KD); whereas subjects with ATN 
were noted to have urine with substantial masses at 11, 11.7, and 14.6 KD. The intensity of these 
peaks were then added together and normalized with the individual components of the discriminate 
peaks representing a percentage of the total. The prerenal and ATN subjects were then randomized 
in a training set consisting of 23 subjects and a testing set consisting of 23 subjects. Multiple linear 
regression was performed on the training set, and this allowed for 65% accuracy when applied to 
the testing set. Feed forward neural networks with hidden neuron layers ranging from 2-10 achieved 
similar predictive capability on the training set and testing sets. 
 
Conclusions: Although the SELDI-TOF methodology may be a useful adjunct in the assessment of 
AKI and renal disease, we suggest that larger training sets will be necessary to effectively exploit 
this strategy. 
 
 
Key Words:  Acute kidney injury, urine proteomics, SELDI, mass spectroscopy 
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 INTRODUCTION 
 
The accurate etiological diagnosis of acute kidney injury continues to require the visual inspection 
of the urine sediment as well as the cognitive skills of a well trained clinician. To assist in the 
distinction between pre- renal azotemia (PRA) and parenchymal acute kidney injury, most notably 
acute tubular necrosis (ATN), differences in renal sodium and water handling in these conditions 
have been utilized.1 While the urinary sodium, creatinine and the calculated indices (e.g., fractional 
sodium excretion) have been employed with some success to differentiate acute tubular necrosis 
(ATN) from pre-renal azotemia (PRA), the ability of these measurements to distinguish between 
ATN and PRA is limited in a number of settings including contrast nephropathy, pigment 
nephropathy, ATN in patients with severe liver disease and patients with non-oliguric ATN.2 
 
It has been known for many years that tubular protein metabolism is altered by conditions 
associated with acute kidney injury. This has been clearly demonstrated in the case of beta 2 
microglobulin where marked elevations in urine beta 2 microglobulin anticipate increases in serum 
creatinine with aminoglycoside toxicity and renal allograft rejection. In fact, the criticism of the 
use of urinary beta 2 microglobulin is that it is “too sensitive” for reliable distinction of ATN or 
other parenchymal acute kidney injury from easily reversible renal injury and/or non-significant 
renal impairment whereas other markers such as Kim1 and NGal have shown greater promise.3 
Hampel and coworkers demonstrated that analysis of urine proteins with surface-enhanced laser 
desorption/ionization (SELDI) – time of flight (TOF) spectroscopy could differentiate those 
patients who developed contrast nephropathy from those who did not develop nephropathy 
following radiocontrast.4  From the exciting data that these workers presented, it seemed clear to 
us that the pattern of urine proteins observed in patients with nephropathy might be used to 
differentiate among the causes of acute kidney injury without necessarily identifying which 
proteins were contributing to these patterns. As neural networks have been employed in the sorting 
of these types of patterns,5 we decided to pursue the following studies. 
 
METHODS 
 
Patient selection: 
 
Written informed consent was obtained from the patient prior to enrollment for the protocol, which 
was approved by the Institutional Review Board.  Patients from the nephrology service at a 
tertiary care center (the Medical College of Ohio) were prospectively enrolled. Co-morbid 
conditions, medication usage, serum electrolytes, blood urea nitrogen, serum and urine creatinine 
were assessed. The clinical diagnosis was discussed and agreed upon by a committee of 4 
nephrologists without knowledge of the SELDI-TOF results (vida infra).  
 
Criteria for acute tubular necrosis (ATN) were: 
1) compatible premorbid clinical course (hypotension, exposure to nephrotoxic agents) 
2) no evidence of obstructive etiology 
3) urine sediment consistent with ATN (e.g., showing renal tubular epithelial cells (RTE), RTE 
and “muddy” casts) 
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 Criteria for prerenal disease was: 
1) compatible premorbid conditions 
2) objective evidence of intravascular volume depletion 
3) clinical improvement with adequate volume repletion 
4) absence of characteristic urine sediment findings for ATN 
 
For the purpose of this report, we focus on those 49 patients who presented with acute kidney 
injury.  In order to develop our model, we initially studied 5 patients with acute tubular necrosis 
(ATN) and 5 patients with prerenal azotemia to identify different patterns on the SELDI-TOF 
spectrum. Once these were identified, we studied all of the remaining patients with AKI, created 
training and testing sets for the neural network analysis. 
 
SELDI-TOF Proteomic Analysis. 
Initial determination of optimum array surface 
 
Surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry was 
used to generate protein profile spectra from the urine specimens. In order to determine the 
optimal conditions and array surface for subsequent pattern profiling, urine specimens from 
different clinical conditions (e.g., control, acute tubular necrosis (ATN), prerenal azotemia) were 
applied under varied conditions to 5 different ProteinChip array (Ciphergen Biosystems, Palo 
Alto, CA) surfaces. After some optimization work (Appendix 1), the H4 ProteinChip array 
(hydrophobic) consisting of 16 methylene groups which bind molecules through interactions with 
hydrophobic amino acids (alanine, valine, phenyalanine, tryptophan, tyrosine, leucine, isoleucine) 
was employed for subsequent studies using the “high” laser setting. 
 
Clean-catch urine specimens (frozen and stored –20’C) were thawed, diluted 1:5 and deposited 
directly onto a 2 mm spot of the H4 ProteinChip arrays. The arrays were allowed to incubate in a 
humidity chamber as specified in the manufacturer’s protocol. The spots were then washed with 
the appropriate washing solution. Twice, one half microliter of energy absorbing matrix (EAM, a 
saturated solution of 3,5-Dimethoxy-4- hydroxycinnamic acid in aqueous 50% acetonitrile and 
.5% trifluoroacetic acid) was applied to the sample and allowed to air dry. The H4 ProteinChip 
array was transferred to a ProteinChip reader and a laser (N2 320 nm- UV) was focused on the 
sample in a vacuum chamber. After 2 warming laser shots, proteins absorbed to the matrix were 
ionized and desorbed from the array surface. Ionized proteins were detected and molecular masses 
were determined using time of flight (TOF) analysis. The TOF mass spectra were collected in the 
positive ion mode with a ProteinChip System (PBSII series, Ciphergen) using Ciphergen Peaks 
(version 2.1b) software. 
Real-time signal averages of 65 laser shots were averaged to generate each spectrum. Data 
were collected without filters and were later used for analyses. Patient samples and controls 
were run at the same time and intermixed on the same chip and on multiple chips. 
 
Regression analysis and neural network design and implementation: 
 
Data analysis was performed using the program MatlabTM (Release R2014a, TheMathWorks, 
Inc.). 
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 Multiple logistic regression was performed using the program “stepwise” from within the curve-
fitting toolbox. 
 
Feed forward neural networks were initially created within the neural network toolbox employing 
the graphical neural network interface, “nntool.”  However, most manipulations of these were done 
from scripts written by the authors (see example in Appendix 2).  Data figures were also created 
from within Matlab TM using resident graphing programs and the statistics toolbox. 
 
RESULTS 
 
Analysis of the urine from the 18 normal patients demonstrated a consistent, substantial, broad 
peak at 84 kD which we attributed to Tamm-Horsefall protein. This was present in every normal 
urine specimen. The peak which we attributed to albumin peak was consistently less than that of 
the adjacent Tamm-Horsefall in all normal subjects (Figure 1). 
 
In order to discriminate amongst patients with AKI, we initially focused on 5 patients with pre-
renal azotemia and 5 patients with ATN that had minimal co-morbidities. These subjects are 
specifically identified in Tables 1 and 2 as index patients. Five peaks with the high laser power 
were identified as potential candidates to discriminate between AKI due to prerenal or ATN 
causes. Representative SELDI spectra are shown for prerenal azotemia in Figure 2 and ATN in 
Figure 3. A comparison of urine spectra from prerenal and ATN subjects is shown in Figure 4. 
 
 
 
Figure 1:  SELDI spectrum obtained from the urine of a normal control subject. X axis is in units    
of 10 kilodaltons (KD). Insert expands region between 6 and 10 KD where Albumin 
(narrow peak centered at around 66.5 KD) and Tamm-Horsfall (broader peak centered 
around 84KD) are detected.  Y axis shows arbitrary detection units. 
58
Kennedy, PhD et al.: Urine SELDI in AKI
Published by Marshall University's Joan C. Edwards School of Medicine, 2016
  
Figure 2:  SELDI spectrum obtained from the urine of a patient with prerenal azotemia. X axis is in    
                  units of 10 kilodaltons (KD). Insert expands region between 6 and 10 KD where  
                  Albumin (narrow peak centered at around 66.5 KD) and Tamm-Horsfall (broader  
                  peak centered around 84KD) are detected.  Y axis shows arbitrary detection units. 
 
 
 
 
Figure 3:  SELDI spectrum obtained from the urine of a patient with prerenal azotemia.  X axis   
                  is in units of 10 kilodaltons (KD). Insert expands region between 6 and 10 KD where  
                  Albumin (narrow peak centered at around 66.5 KD) and Tamm-Horsfall (broader  
                 peak centered around 84KD) are detected.  Y axis shows arbitrary detection units. 
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Figure 4: Urine SELDI spectra from patients with prerenal azotemia (PRE, lower panels) and  
     acute tubular necrosis (ATN, upper panels) contrasted over ranges between 1.1 and  
     1.5 KD (left panels) and 2 and 5 KD (right panels). 
 
 Table 1:   
 
Pre-Renal 
Azotemia 
 
Renal Co-Morbidity 
 
Age 
 
Oliguric 
FENa 
(%) 
 
Index Patient 
1  60 X 0.68 x 
2  36 X 0.10 x 
3 HIV Nephropathy 37  1.39  
4  45 X 0.13 x 
5  71 X 0.82 x 
6 Diabetes with Proteinuria 61 X 0.32  
7  52 X 0.82 x 
8 CKD3, Hypertension 78  .015  
9  65 X .018  
10  56 X 0.53  
11  62 X 0.75  
12 CKD3, Hypertension 62 X 1.04  
13  52 X 0.68  
14 CKD3, Hypertension, Proteinuria 68  5.64  
15  66 X 0.22  
16  65 X 0.28  
17 CKD3, Diabetes, Proteinuria 62  1.15  
CKD - refers to chronic kidney disease.  The Staging is as per NKF guidelines with CKD3 
referring to an estimated glomerular filtration rate (eGFR) < 60 ml/min and CKD4 implying the 
eGFR<30.  FENa refers to the fractional excretion of sodium expressed in percent.  Index patients 
were those used to identify the initial SELDI peaks used in discrimination. 
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 Table 2: 
 
Acute 
Tubular 
Necrosis 
 
Renal Co-Morbidity 
 
Oliguric 
 
Age 
 
FENa (%) 
 
Index Patient 
1   45 0.30  
2  X 68 6.32 X 
3 CKD3, Proteinuria X 62 2.52  
4  X 64 7.58 X 
5  X 62 4.89 X 
6 CKD3  50 2.23  
7   42 0.18  
8  X 67 2.00 X 
9  X 77 4.77 X 
10   50 0.37  
11 CKD3, Hypertension  49 0.28  
12 Liver failure X 68 2.25  
13 Rhabdomyolysis X 77 2.95  
14 CKD3 X 70 3.27  
15   73 1.58  
16   90 0.07  
17  X 60 3.22  
18 CKD4 X 49 2.65  
19 CKD3 X 74 3.28  
20 CKD3 X 66 2.65  
21  X 72 5.67  
22   69 1.87  
23   39 0.68  
24   92 0.47  
25 CKD3 X 88 2.11  
26   48 0.71  
27   36 1.04  
28 CKD3 X 51 1.95  
29   56 0.82  
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 Linear regression was performed using the “regress.m” function (see Appendix A). Although a 
variety of feed forward neural networks were tried, best results occurred with 10 hidden neurons, 
a tansig transfer function and the trainlm (Levenberg-Marquardt) algorithm. Details regarding the 
training parameters are shown in Appendix A. A representative performance of this training with 
12 hidden neurons is shown in Figure 5. 
 
Results of this analysis are shown in Table 3. As is shown, both the linear regression and neural 
network strategies led to 65% accuracy on the testing set. 
 
Interestingly, 3 out of 17 patients with pre-renal azotemia had an FENa > 1% whereas 8 of the 29 
subjects with ATN had an FENa < 1% (Tables 1 and 2, respectively). The accuracy of the FENa on 
this population (assuming the clinical assignment was accurate) was 76%. 
 
Table 3: 
Strategy Training Set Testing Set %Correct 
Testing 
 Pre ATN Pre ATN  
Clinical 7 14 11 25  
Linear 
Regression 
True=6 
False=3 
True=13 
False=1 
True=1 
False=7 
True=14 
False=1 
65% 
FFNN True=8 
False=1 
True=13 
False=1 
True=3 
False=5 
True=13 
False=2 
 
65%  
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Figure 5:  Graph illustrating neural network training with a training subset (blue),  
                  testing subset (red) and validation subset (green) all drawn randomly from the 23  
                  testing subjects as per MatlabTM software, see Appendix 2. Network established by  
                  this method then applied to 23 testing subjects described in methods with results  
                  reported in Table 1. 
 
 
DISCUSSION 
 
There are two points which our experience has taught us. First and probably foremost, Tamm 
Horsfall was quite prominent in all control subjects. Rather than looking like control urine, we 
noted that the pre-renal subjects’ urine had markedly less of the peak attributed to Tamm Horsfall 
protein and a pattern quite distinct from normal urine specimens. This should, perhaps not be 
surprising. It demonstrates that renal ischemia sufficient to impair renal function has 
consequences on urine protein excretion, a phenomenon noted by other workers in this area.3,6,7 
 
In addition, our data suggest that screening urine proteins with SELDI-TOF could potentially assist 
clinicians in the differential diagnosis of acute kidney injury. Although our study was quite 
preliminary, we were able to identify candidate peaks that had some discriminatory possibility. 
Although it is premature to comment, it is certainly possible that some of our candidate peaks 
correspond to previously described urinary biomarkers.3 We emphasize however that masses 
measured with the SELDI-TOF method may not correspond directly to actual masses and therefore 
identification of specific proteins will require more detailed analysis.8-11 It is possible that with 
more detailed analyses, other candidate peaks offering discriminatory power might be identified. 
Perhaps most importantly, larger sample sizes will be necessary to develop and test the utility of 
urine SELDI-TOF as a clinical tool in the differential diagnosis of acute kidney injury. 
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 Appendix 1: 
 
Surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry was 
used to generate protein profile spectra from the urine specimens. In order to determine the 
optimal conditions and array surface for subsequent pattern profiling, urine specimens from 4 
different conditions (control, proteinuria, acute tubular necrosis, interstitial nephritis) were applied 
under varied conditions to 5 different ProteinChip array (Ciphergen Biosystems, Palo Alto, CA) 
surfaces. The different array surfaces, which employ varied means of binding and retaining 
proteins and peptides based on physical interactions, included: 
 
1) The SAX ProteinChip array (strong anion exchanger) consisting of a cationic surface of 
ammonium groups which binds negatively charged molecules. 
2) The WCX2 ProteinChip array (weak cation exchanger) consisting of an anionic surface of 
carboxylate groups which binds positively charged molecules. 
3) The IMAC ProteinChip array (immobilized metal affinity capture) consisting of metal 
chelating surface which binds molecules based on affinity of amino acid residues for 
various metal ions. 
4) The NP1 ProteinChip array (normal phase) consisting of silicon dioxide surface which 
binds molecules based on electrostatic and dipole-dipole interactions. 
5) The H4 ProteinChip array (hydrophobic) consisting of 16 methylene groups which bind 
molecules through interactions with hydrophobic amino acids (alanine, valine, 
phenyalanine, tryptophan, tyrosine, leucine, isoleucine). 
 
All experiments were performed according to standard protocols supplied by the manufacturer. 
Experiments carried out on the IMAC ProteinChip array used 100 mM solutions of nickel sulfate 
and zinc sulfate as the source of nickel and zinc ions responsible for binding molecules with 
histidine, tryptophan, and cysteine residues. For experiments carried out on the SAX and WCX2 
ProteinChip arrays, binding and washing stringency was conferred using .05 M solutions of sodium 
acetate (pH 4), sodium phosphate (pH 6), Tris buffer (pH 8) and sodium carbonate (pH 10). For 
experiments carried out on NP1 and H4 ProteinChip arrays, binding and washing stringency was 
conferred using 10%, 25%, 50%, and 100% acetontrile.  Additionally, all chips were analyzed 
under low (250) and high (300) laser intensity in order to increase the sensitivity of  peak detection 
to ionize and desorb molecules with both low (≤ 20 KDa) and high (>20 KDa) molecular weights. 
 
Clean-catch urine specimens frozen at –20’C were thawed.  All samples were diluted 1:5 and 
deposited directly onto a 2 mm spot of the respective ProteinChip arrays (final volume of 1 L 
sample and 4 L of the respective binding solution) which had been pre- incubated for 10 minutes 
with 50% acetontrile. The arrays were allowed to incubate in a humidity chamber for the various 
times specified in the manufacturer’s protocol. The spots were then washed with the appropriate 
washing solution. Twice, one half microliter of energy absorbing matrix (EAM, a saturated solution 
of 3,5-Dimethoxy-4- hydroxycinnamic acid in aqueous 50% acetonitrile and .5% trifluoroacetic 
acid) was applied to the sample and allowed to air dry. 
 
 
The ProteinChip array was transferred to a ProteinChip reader and a laser (N2 320 nm- UV) was 
focused on the sample in a vacuum chamber. After 2 warming laser shots, 
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 proteins absorbed to the matrix were ionized and desorbed from the array surface. Ionized proteins 
were detected and molecular masses were determined using TOF analysis.  The TOF mass spectra 
were collected in the positive ion mode with a ProteinChip System (PBSII series, Ciphergen) using 
Ciphergen Peaks (version 2.1b) software.  Real-time signal averages of 65 laser shots were 
averaged to generate each spectrum.  Data were collected without filters and were later used for 
analyses. 
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 Appendix 2: 
 
%Neural Net program 
% put all training and testing sources into trainv and testv 
% put respectivce targets into t and tt. Alternatively, just 
% define total set of source as p1 and target as t1 and elimate the code on 
% lines 9 and 10 
 
 
% CODE TO DIVIDE THE DATA INTO TRAINING & TESTING SETS 
p1=cat(2,trainv,testv); 
t1=cat(2,t,tt); 
 
 
% CODE TO DIVIDE THE DATA INTO TRAINING & TESTING SETS 
% uses 1/2 testing and 1/2 training 
[TrainV, ValV, TestV]=dividevec(p1,t1,0,0.5); 
 
 
%***************************************************** 
Epochs=100; %Set the Number of Epochs to Run in the Neural 
Network Goal=0.0; %Set the Performance Goal of the Neural 
Network S_Hidden1=10; %Set the Number of Neurons in the Hidden 
Layer S=S_Hidden1; clear S_Hidden1 
 
% CODE TO SETUP THE NEURAL NETWORK 
net=newff(TrainV.P, TrainV.T, S, {'tansig', 
'purelin'},'trainlm'); net=init(net); % Initialize network 
net.trainParam.epochs = 
Epochs; net.trainParam.goal = 
Goal; net.trainParam.min_grad 
= 1e-12; 
net.trainParam.max_fail = 10; 
 
% Train the neural network 
[net,tr]=train(net,TrainV.P,TrainV.T)
; 
 
% Simulate the neural 
network 
Ytrain=sim(net,TrainV.P)
; 
Ytest=sim(net,TestV.P); 
Yval=sim(net,ValV.P); 
 
 
%***************************************************** 
% CALCULATE SOME STATISTICAL MEASUREMENTS TO EVALUATE THE ACCURACY OF THE 
% NETWORK SIMULATION OUTPUTS (PREDICTIONS) 
 
%***************************************************** 
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% CALCULATE SOME STATISTICAL MEASUREMENTS TO EVALUATE THE ACCURACY OF THE 
% NETWORK SIMULATION OUTPUTS (PREDICTIONS) 
 
% Calculate the Error 
YError_train=round(TrainV.T-Ytrain)  %Error in the Training 
Set YError_test=round(TestV.T-Ytest) %Error in the Testing Set 
[k h]=size(TrainV.P); 
m=cat(2,ones(h,1),TrainV.P'); 
 
 
[b,bint,r,rint,stats] = 
regress(TrainV.T',m); c=zeros(h,1); 
for i=1:h 
for 
j=1:k+1 
c(i)=c(i)+b(j)*m(i,j); 
 
end 
end 
 
 
fprintf('Results of "regress" are:\n'); 
fprintf(' R^2 F-Statistic p error 
variance\n'); disp(stats) 
 
[k h]=size(TestV.P); 
zz=cat(2, ones(h,1),TestV.P'); 
cc=zeros(h,1); 
for i=1:h 
for 
j=1:k+1 
cc(i)=cc(i)+b(j)*zz(i,j); 
 
end 
end 
diary foo.out 
Train_RES=round(c-
TrainV.T'); 
Test_RES=round(cc-TestV.T'); 
A=cat(2,TrainV.T',round(Ytrain)',round(c)) 
AA=cat(2,TestV.T',round(Ytest)',round(cc)) 
diary 
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